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Abstract A P1 clone containing the gene for human glutathione
dependent PGE synthase (PGES) was isolated and character-
ized. The gene is divided into three exons, spans 14.8 kb and was
localized to chromosome 9q34.3. In A549 cells, the protein and
activity levels of PGES were increased by interleukin-1L. This
increase was prevented by phenobarbital. Reporter constructs
containing the 5P-flanking region of exon 1, which exhibited
strong promoter activity, responded accordingly, except that
interleukin-1L induced a transient increase followed by a
decrease. As cyclooxygenase 2 expression has been reported to
respond in a similar fashion, a transcriptional regulatory basis
for the observed co-regulation with PGES is implied. The strong
down-regulation by phenobarbital raises important issues con-
cerning its mechanisms of action.
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1. Introduction
The isoenzymes cyclooxygenase (COX)-1 and COX-2 cata-
lyze the double oxygenation and reduction of arachidonic
acid, leading to the formation of prostaglandin endoperoxide
H2. This intermediate serves as substrate for several terminal
prostanoid synthases like the recently characterized human
glutathione dependent prostaglandin E synthase (PGES) [1].
This enzyme represents an inducible member of the MAPEG
superfamily [2]. Other members are microsomal glutathione
transferase 1 (MGST1), MGST2 and MGST3, which all are
glutathione transferases and glutathione dependent peroxi-
dases. The family also includes 5-lipoxygenase activating pro-
tein (FLAP) and leukotriene C4 synthase, which are crucial
for leukotriene biosynthesis. PGES is most closely related to
MGST1, demonstrating 38% identity on the amino acid se-
quence level. The gene encoding MGST1 resides on chromo-
some 12 [3] and consists of three coding exons and one ¢rst
non-coding exon [4]. Later studies have demonstrated the
presence of several alternative non-coding ¢rst exons [5,6] of
which one is predominant. Other MAPEG genes (FLAP and
LTC4 synthase) that have been characterized consist of ¢ve
exons.
The chromosomal localization of all MAPEG members ex-
cept PGES is known. LTC4 synthase, FLAP, MGST2 and
MGST3 map to chromosomes 5q35, 13q12, 4q28^31 and
1q23, respectively [7^10]. Interestingly, LTC4 synthase, which
plays a role in bronchial asthma, localizes in a region harbor-
ing several genes involved in in£ammation [7]. Cyclooxy-
genases 1 and 2 have been localized to chromosomes 9q32^
33.3 and 1q25.2^25.3 [11^13].
Cyclooxygenase 2 and PGES are induced by the proin£am-
matory cytokine interleukin-1L (IL-1L) suggesting the possi-
bility of a common gene regulatory mechanism [1]. Several
reports have demonstrated that PGES, COX-2 and phospho-
lipase A2 form an inducible pathway for e⁄cient and pre-
ferred PGE2 production [14,15].
Here we report the PGES gene structure1, localization and
certain regulatory properties. These data form an essential
basis for obtaining a better understanding of the link between
COX-2 and PGES in particular, and the interplay between
MAPEG members, cyclooxygenases and lipoxygenases in in-
£ammation and other pathophysiological conditions in gener-
al.
2. Materials and methods
2.1. Cell culture
A549 human alveolar cells were maintained in DMEM containing
4500 mg/l glucose, 10% fetal calf serum, 1 mM sodium pyruvate,
100 U penicillin/ml and 100 Wg streptomycin/ml.
2.2. Genomic cloning and chromosomal localization
Genomic cloning and subsequent chromosomal localization was
performed by Genome Systems, Inc. A P1 genomic library was
screened by hybridization using a cDNA probe consisting of the cod-
ing region of PGES that was labeled by random priming. The P1
clone obtained was denoted: 18096 (96) with clone address: DMP-
HFF#1-569G12. Puri¢ed DNA from this clone was labeled with di-
goxigenin dUTP by nick translation. Labeled probe was combined
with sheared human DNA and hybridized to metaphase chromosomes
derived from PHA stimulated peripheral blood lymphocytes in a so-
lution containing 50% formamide, 10% dextran sulfate and 2USSC.
Speci¢c hybridization signals were detected by incubating the hybrid-
ized slides in £uoresceinated antidigoxigenin antibodies followed by
counterstaining with DAPI for one color experiments. Probe detection
for two color experiments was accomplished by incubating the slides
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in £uoresceinated antidigoxigenin antibodies as well as avidin Texas
red followed by counterstaining with DAPI. The initial experiments
resulted in the speci¢c labeling of the long arm of a group C chro-
mosome that was believed to be chromosome 9 on the basis of size,
morphology, and banding pattern. A second experiment was con-
ducted in which a biotin labeled probe, which is speci¢c for the het-
erochromatic region of chromosome 9, was cohybridized with clone
18096. This experiment resulted in the speci¢c labeling of the hetero-
chromatin in red and the long arm in green of chromosome 9. Ob-
servation of speci¢cally labeled chromosomes 9 demonstrated that
clone 18096 is located at the terminus of the long arm of chromosome
9, an area that corresponds to band 9q34.3 [16]. A total of 80 meta-
phase cells were analyzed with 71 exhibiting speci¢c labeling. Our
chromosomal localization is in agreement with preliminary
AC007936 from which primer sequences were constructed, but is in
con£ict with chromosomal localization assigned for preliminary
AC015667.
2.3. Organization and sequence of the PGES gene
The sequence of the human PGES gene was determined by PCR
and sequence analysis according to the strategy shown in Fig. 1A,
using the P1 clone 18096 as template. All exons and exon/intron
boundaries were sequenced in both directions. PCR reactions were
performed in 1.5 mM MgCl, 0.15 mM dNTP, 10% DMSO, 0.5 U
Taq Polymerase (Sigma) and were carried out in 30 cycles, each in-
volving denaturation at 94‡C, 45 s, annealing at 53‡C, 45 s, elongation
at 72‡C, 1 min, followed by 7 min elongation. The PCR products were
puri¢ed using high pure PCR puri¢cation kit (Boehringer, Germany)
and the sequence analyzed using the big dye terminator kit (Perkin
Elmer) and an ABI model 373 DNA sequencer.
2.4. Gene reporter constructs
Two human PGES promoter fragments including 3651/320 and
3190/320 (numbering the translation start site +1) were generated by
PCR ampli¢cation, using a P1 clone as template, two sense primers
(oligonucleotides U-promKpnI and U-promSacI, Table 1) and one
common antisense primer (oligonucleotide L-promBglII, Table 1).
The PCR products were cleaved with the appropriate restriction en-
zyme, gel-puri¢ed (Pharmacia) and subcloned into the KpnI/BglII and
SacI/BglII sites of pGL2Basic reporter vector (Promega), resulting in
the constructs pGL2^651 and pGL2^190 respectively. The sequences
were veri¢ed by sequence analysis as described above. Plasmids were
puri¢ed using the Qiagen endotoxin free kit.
2.5. Transfection assay
The A549 cells were plated in 35 mm 6-well plates at 4U105 cells
per well and incubated overnight. The cells were transfected using
Superfectin (Qiagen), 2.5 Wg of PGES reporter construct and 5 Wg
of L-galactosidase control vector (Promega). Cells were incubated
for 3 h at 37‡C, then transfection solution was replaced with fresh
media. 48 h later, cells were harvested and luciferase and L-galactosi-
dase activities were determined. Transfected cells were treated with
IL-1L, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and phenobarbi-
tal (PB) for 16 h before analysis. IL-1L was added in the presence of
2% FCS. Luciferase activity was determined using luciferase assay
reagent (Promega) and L-galactosidase activity was measured using
ortho-nitrophenyl L-D-galactopyranoside (Sigma) as substrate. All val-
ues were corrected for endogenous galactosidase activity. The lucifer-
ase value was always divided by the L-galactosidase value in order to
correct for transfection e⁄ciency.
2.6. Western blot and PGES activity analysis
The method for preparing microsomes, analyzing for PGES activity
as well as protein expression by Western blot has been described in
detail [1].
2.7. Reverse transcriptase-PCR (RT-PCR)
Total RNA was extracted with Trizol (Life Technology) from A549
cells incubated 0, 2, 4 and 6 h in the presence of IL-1L (1 ng/ml). RT
reactions were performed using 5 Wg of RNA, 1 Wl of an poly(dT)-
oligo (Stratagene) and 200 units of SuperscriptTMII (Life Technol-
ogy). For ampli¢cation of PGES, exon 3 speci¢c primers U-2MGST4
and L-2MGST4 (Table 1) were used. As a control, constitutively ex-
pressed human L-actin mRNA was also ampli¢ed with the primers
L-sense and L-antisense (Table 1). PCR reactions were performed as
described above. All PCR products were analyzed on 1% agarose gels.
2.8. Sequence analysis
Computer analysis of the 5P-£anking region of the human PGES for
potential transcription factor binding sites was performed with Mat-
Inspector 2.2 [17].
3. Results
3.1. Genomic cloning and chromosomal localization
Using the coding sequence of PGES as probe, a genomic P1
library was screened and a genomic clone was obtained. This
P1 clone (18096) was subsequently used to characterize the
gene and promoter (see below) but also as a probe for chro-
mosomal localization by £uorescence in situ hybridization.
Based on cohybridization with another probe speci¢c for the
heterochromatic region of chromosome 9 and fractional
length measurements, it was concluded that the PGES ge-
nomic clone is located at the terminus of the long arm of
chromosome 9, an area that corresponds to band 9q34.3.
3.2. Gene organization
Fig. 1B contains the complete sequence of the human PGES
exons, together with intron^exon junctions and 632 bp up-
stream of exon 1. As shown, the PGES gene is split into three
exons (W136, 83 and 1526 nt) by two introns and spans a
region of approximately 14.8 kb. Exon^intron junctions fol-
low the GT-AG rule except for the 5P-site of intron 2, which
consists of GC instead of GT. The intron sizes are 4.2 kb and
8.8 kb respectively. A 682 bp fragment containing the
5P-£anking region of exon 1 is shown in Fig. 1B. This putative
promoter is GC-rich and lacks a TATA box at a functional
site. Computer analysis of the promoter revealed numerous
potential transcription factor binding sites. Two GC-boxes,
two tandem barbie boxes and an AHR (aryl hydrocarbon
response element) were identi¢ed. The 3P-end of exon 3 con-
Table 1
Sequences of oligonucleotides
Primer Fig. 1A Sequencea
PCR/sequence analysis
(Fig. 1)
U-prompges1 1 ggctggaattacaggtgtga
U-promPGEseq 2 agaggcccctggtattccttg
U-PGES-1 4 gtgctggctgcaggaaggct
L-PGES-1 7 tgctcacctcccagccctgca
U-PGES-2 6 aactgcacctctgtcctgcca
L-PGES-2 8 ggaacacagaaaacctcagcc
U-PGES-3 9 gatttgagtgtgtgatatgcc
L-PGES-3 11 ttagctgaaggattttctatc
L-PGES-3b 12 gcaacatggtgaacccgtct
U-2MGST4 10 aacgacatggagaccatctac
U-PGES-3c 14 ggattacaggcgcgtatcac
L-PGES-3d 13 cagggaacaccaggaacgcg
Exon speci¢c primers
RT-PCR
U-2MGST4 aacgacatggagaccatctac
L-2MGST4 acatcaagtccccaggtatagcc
L-Actin speci¢c primers
U-sense gattcctatgtgggcgacgag
L-antisense ccatctcttgctcgaagtcc
Reporter construct prim-
ers
U-promKpn1 3a gagaggtacccagataaact
U-promSac1 3b gcttcttggagctccggcaa
L-promBgl2 5 tctctcagatctgtgggtgtg
aRestriction enzyme sites used for cloning are underlined.
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tains a polyadenylation signal (underlined in Fig. 1B) 32 nt
upstream of the polyA observed in cDNA clone AF027740.
Our sequence is in general agreement with a preliminary
deposited sequence (AC007936, contig nt: 100 506^117 518),
from which intron sizes were deduced, with an exception in
the 3P non-coding end of the gene where a GT-dinucleotide
repeat is located. In our P1 clone 22 repeats were determined
whereas in clone AC007936 24 repeats were noted. Two nt in
AC007936, A16 and A49 were determined as C in our P1
clone (numbered from the initiator ATG). A nucleotide di¡er-
ence in the coding region (T183C), as compared to cDNA
clone AF027740 was also identi¢ed, which does not alter
the amino acid sequence. Three nucleotides, AGG at positions
+165^167 in the cDNA clone coding region AF010316, are
not present in our P1 genomic sequence. Several di¡erences in
the 3P region to AC007936 and AF027740 were also noted.
3.3. Transcriptional activity of the putative PGES gene
promoter
Transcriptional activity of the 5P-£anking region of human
Fig. 1. Structure and sequence of the human PGES gene. A: Structure of the human PGES gene. Introns and £anking sequences are repre-
sented by solid lines. Exons are represented by boxes; the open boxes and solid boxes indicate the non-coding regions and coding regions, re-
spectively. Beginning of ¢rst exon is unknown. Also indicated are the primers used in PCR analysis, and the PCR products used for sequence
analysis. B: The nucleotide sequence of the human PGES gene, exons (uppercase bold letters) and partial introns (lowercase letters) and 632
bp of the 5P-£anking region (uppercase). GC-boxes and barbie boxes are underlined and an AHR site is indicated with italics. The predicted
polyadenylation signal and ATG translation start site are underlined.
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PGES gene was examined in A549 cells, transiently trans-
fected with reporter constructs containing 190 bp and 651
bp of the putative promoter (pGL2^190 and pGL2^651)
and a promoterless vector (pGL2Basic) as negative control.
As shown in Fig. 2A both the pGL2^190 and pGL2^651
constructs increase luciferase expression, by 25- and 35-fold,
respectively compared to the negative control. It appears that
the cis-acting elements needed for the basal expression are
included in the 171 bp fragment. This region contained two
potential GC-boxes 119 and 107 bases upstream from the
translation start site. Since the 5P-£anking region contains
putative cis-acting elements such as barbie boxes and an
AHR site, we stimulated transfected A549 cells with chemicals
known to act via these regulatory elements. TCDD did in-
crease luciferase expression 1.5-fold whereas 0.2 mM and
2 mM phenobarbital decreased expression 0.7-fold and almost
completely (Fig. 2B).
3.4. IL-1L induction of PGES mRNA expression
RT-PCR analysis showed that the transcript of PGES
mRNA was stimulated by IL-1L in A549 cells (Fig. 3). An
induction of mRNA was seen 4 h after exposure, followed by
a decline. The same pattern was shown with transient trans-
fections of A549 cells with the pGL2^651 reporter construct
(Fig. 2B and data not shown).
3.5. Phenobarbital depresses the induction of PGES in
A549 cells
A549 cells were treated with phenobarbital and/or IL-1L for
72 h. Microsomal fractions were prepared and analyzed for
PGES expression by SDS^PAGE and Western blotting. Fig. 4
demonstrates that IL-1L induced PGES expression was
blocked by treatment with phenobarbital. PGES activity mea-
surements were consistent with the Western blot data (not
shown).
4. Discussion
The PGES gene is located on chromosome 9q34.3, and it
now appears that all known MAPEG members reside on dif-
ferent chromosomes. The gene structure of PGES is similar to
its closest relative MGST1 with regards to exon/intron bor-
ders [4] and di¡ers from other human MAPEG members,
which consist of additional exons. Interestingly, the lipoca-
Fig. 2. Functional analysis of the human PGES promoter in A549
cells. A: Human PGES promoter fragments (3651/320 and 3190/
320) were subcloned upstream of the ¢re£y luciferase reporter gene
in the pGL2Basic vector. A549 cells were transiently transfected
with the constructs. As a negative control the cells were transfected
with promoterless plasmid pGL2Basic. The bar graph represents
mean þ S.E.M. from three experiments performed in duplicate and
the luciferase expression was normalized to the transfection e⁄-
ciency by L-galactosidase expression. Data are expressed in relation
to the promoterless plasmid. B: E¡ects of TCDD, phenobarbital
and IL-1L on the transcriptional activity of the PGES 5P-£anking
region. A549 cells transfected with pGL2^190 were cultured in the
presence of 125 nM TCDD, 0.2 mM or 2 mM phenobarbital for 16
h. A549 cells transfected with pGL2^651 were cultured in the pres-
ence of IL-1L (1 ng/ml) for 16 h. The bar graph represents mean þ
S.E.M. from three experiments performed in duplicate. Data are ex-
pressed as relative change compared to unstimulated cells.
Fig. 3. IL-1L induction. RT-PCR analysis of PGES mRNA from
A549 cells exposed to 1 ng/ml IL-1L for the indicated periods of
time. The upper panel shows PCR products from L-actin mRNA,
and the bottom panel shows PCR products generated from human
PGES mRNA (exon 3 speci¢c product 313 bp).
Fig. 4. E¡ect of phenobarbital on IL-1L induced PGES expression.
Western blot analysis of PGES expression in microsomal fractions
of A549 cells incubated with phenobarbital (PB) and/or IL-1L. As
positive control (PGES), the membrane fraction from bacteria ex-
pressing human PGES was included (1 Wg). In all other lanes, 10 Wg
of total protein was analyzed.
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lin-type PGD synthase as well as COX-1 genes map to the
same part of chromosome 9 as PGES, i.e. 9q34.2^q34.3 [18]
and 9q32^33.3 [12,13], respectively. The putative promoter
region of PGES is transcriptionally active and we have ob-
served that reporter constructs are regulated by IL-1L and
phenobarbital. In A549 cells, a transient rise in PGES
mRNA and promoter activity was observed following expo-
sure to IL-1L. The IL-1L induction of COX-2 mRNA as well
as COX-2 promoter activity has been shown to follow a sim-
ilar pattern [19].
Phenobarbital is a potent inducer of drug metabolizing en-
zymes, inhibits some tumor forms in humans, and is an e¡ec-
tive anticonvulsant as well as sedative. The presence of a
barbie box in the promoter led us to investigate the e¡ect of
phenobarbital on the expression of PGES. Interestingly, phe-
nobarbital strongly reduced PGES promoter activity and in-
duction by IL-1L of PGES protein. This e¡ect may have
broad implications in the context of a role of PGE2 in
sleep/wakefulness since PGD2 and the lipocalin-type PGD
synthase have been suggested to play a role in sedation and
sleep [20]. In addition, PGE2 has been reported to counteract
the e¡ect of PGD2 [21] as well as to be present at higher levels
during wakefulness [22]. A balance of these prostaglandins
might thus control vital CNS functions. Interestingly, COX-
2 activity has been shown to increase after phenobarbital
treatment of Kupfer cells [23]. A possible mechanism for sleep
induction by phenobarbital may therefore involve induction
of COX-2 with down-regulation of PGES, thus leading to a
shift from PGE2 to PGD2 biosynthesis.
In conclusion, here we report the ¢rst gene structure of a
PGES gene. Our results and observations on regulatory prop-
erties form the basis for further research into the physiological
function of PGES in health and disease.
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